KZR

Company Overview — What Does Kezar Life Sciences, Inc. Do?

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California. Kezar Life Sciences, Inc. (KZR) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO John Fowler and employs approximately 60 people. With a market capitalization of $55M, KZR is one of the notable companies in the Healthcare sector.

Kezar Life Sciences, Inc. (KZR) Stock Rating — Hold (April 2026)

As of April 2026, Kezar Life Sciences, Inc. receives a Hold rating with a composite score of 31.5/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.KZR ranks #1,732 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Kezar Life Sciences, Inc. ranks #173 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

KZR Stock Price and 52-Week Range

Kezar Life Sciences, Inc. (KZR) currently trades at $7.37. The stock gained $0.02 (0.3%) in the most recent trading session. The 52-week high for KZR is $7.45, which means the stock is currently trading -1.1% from its annual peak. The 52-week low is $3.53, putting the stock 108.6% above its annual trough. Recent trading volume was 46K shares, suggesting relatively thin trading activity.

Is KZR Overvalued or Undervalued? — Valuation Analysis

Kezar Life Sciences, Inc. (KZR) carries a value factor score of 10/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.78x, versus the sector average of 2.75x.

At current multiples, Kezar Life Sciences, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Kezar Life Sciences, Inc. Profitability — ROE, Margins, and Quality Score

Kezar Life Sciences, Inc. (KZR) earns a quality factor score of 24/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -88.2%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -80.6% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

KZR Debt, Balance Sheet, and Financial Health

Kezar Life Sciences, Inc. has a debt-to-equity ratio of 9.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 11.52x, indicating strong short-term liquidity. Total debt on the balance sheet is $7M. Cash and equivalents stand at $39M.

KZR has a beta of 0.76, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Kezar Life Sciences, Inc. is 40/100, reflecting average volatility within the normal range for its sector.

Kezar Life Sciences, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Kezar Life Sciences, Inc. reported revenue of $0 and earnings per share (EPS) of $-7.66. Net income for the quarter was $-62M. Operating income came in at $-66M.

In FY 2025, Kezar Life Sciences, Inc. reported revenue of $0 and earnings per share (EPS) of $-7.66. Net income for the quarter was $-56M. Operating income came in at $-59M.

In Q3 2025, Kezar Life Sciences, Inc. reported revenue of $0 and earnings per share (EPS) of $-1.53. Net income for the quarter was $-11M. Operating income came in at $-12M.

In Q2 2025, Kezar Life Sciences, Inc. reported revenue of $0 and earnings per share (EPS) of $-1.87. Net income for the quarter was $-14M. Operating income came in at $-15M.

Over the past 8 quarters, Kezar Life Sciences, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing KZR stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

KZR Dividend Yield and Income Analysis

Kezar Life Sciences, Inc. (KZR) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

KZR Momentum and Technical Analysis Profile

Kezar Life Sciences, Inc. (KZR) has a momentum factor score of 60/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 14/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

KZR vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Kezar Life Sciences, Inc. (KZR) ranks #173 out of 838 stocks based on the Blank Capital composite score. This places KZR in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing KZR against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full KZR vs S&P 500 (SPY) comparison to assess how Kezar Life Sciences, Inc. stacks up against the broader market across all factor dimensions.

KZR Next Earnings Date

No upcoming earnings date has been announced for Kezar Life Sciences, Inc. (KZR) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy KZR? — Investment Thesis Summary

Kezar Life Sciences, Inc. presents a balanced picture with arguments on both sides. The quality score of 24/100 flags below-average profitability. The value score of 10/100 indicates premium valuation. Price momentum is positive at 60/100, suggesting the trend favors buyers.

In summary, Kezar Life Sciences, Inc. (KZR) earns a Hold rating with a composite score of 31.5/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on KZR stock.

Related Resources for KZR Investors

Explore more research and tools: KZR vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare KZR head-to-head with peers: KZR vs AZN, KZR vs SLGL, KZR vs VMD.